Inovio Pharmaceuticals
INO | NASDAQ
$1.40
-$0.03 (-2.10%)
At close: Nov 16, 2026, 4:00 PM ET
$1.40
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:54 PM ET
-2.10%
(1D)No price chart data available for 1D timeframe.
Rating
46.5
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #356/1021 (Top 35%)
Key Statistics
Market Data
Market Cap $138.09M
1D Range
1.37 1.48
52W Range
0.60 2.60
Valuation (TTM)
PE -1.75
PB -4.07
EV/EBITDA -1.41
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $4.00
Cash Flow
FCF Yield -39781.4%
SBC Adj. FCF Yield -41473.1%
SBC Impact -4.3%
Margins
Gross Margin -401.7%
Operating Margin -25953.8%
FCF Margin -18378213.7%
Growth (CAGR)
Revenue 3Y | 5Y -29.5% |
-46.0%
Dil EPS 3Y | 5Y 82.8% |
-22.0%
FCF 3Y | 5Y -149.2% |
-98.6%
Returns
ROA -118.3%
ROE -46473.1%
ROIC 291.2%
Financial Health
Net Cash
$48.36M
Current Ratio 0.57
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associat...
Sector Healthcare
Industry Biotechnology
Employees 112
IPO Date Dec 8, 1998
Website www.inovio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.5
Miss -141.93%
YoY:
+42.53% REV
$298.9K
Beat +298.53%
Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$4.00
Upside
+185.71%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove INO